Russia's Biocad to launch new anti-cancer drug in domestic market
Russia’s leading biotech firm Biocad is finishing clinical trials of a new anti-cancer drug that will soon appear in the Russian market and will be able to compete with imported analogues, according to recent statements by Russian Minister of Health Veronika Skvortsova, reports The Pharma Letter’s local correspondent.
It is planned that the new drug will be launched in the Russian market in one to five years and is expected to be significantly cheaper than its foreign equivalents, which are currently imported from abroad.
The new drug is known as PD-1, which is the name of the active protein of the drug. The protein interacts with the tumor, making it visible to the human immune system. The drug - the so-called check-point inhibitor – is designed for the treatment of melanoma, a disease that leads to the death of 70% of patients with this skin cancer in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze